Stimulation of expansion of Tregs with IL-2 and TGF-β1 resulting in decreased Tregs/Th17 ratio along with PD-L1 Fc administration can be a novel therapeutic approach for managing preeclampsia. The gene discussed is IL2; the disease is preeclampsia.